story of the week
Bivalirudin Plus a High-Dose Infusion vs Heparin Monotherapy in Patients With STEMI Undergoing Primary PCI
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
Lancet 2022 Nov 04;[EPub Ahead of Print], Y Li, Z Liang, L Qin, M Wang, X Wang, H Zhang, Y Liu, Y Li, Z Jia, L Liu, H Zhang, J Luo, S Dong, J Guo, H Zhu, S Li, H Zheng, L Liu, Y Wu, Y Zhong, M Qiu, Y Han, GW StoneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.